101. Peru's position on these agenda items has not changed. However, we would like to refer specifically to the relationship between the TRIPS Agreement and the Convention on Biological Diversity (the CBD). We believe it is necessary to reiterate, as a first point and as a matter of principle, the need to fulfil the mandate we undertook in Doha to examine this issue.
102. The status quo of the past several years is causing significant harm to many Members. I highlight the case of my own country, which is dealing with misappropriation of its genetic resources and associated traditional knowledge, as reported by our National Commission for the Protection of Access to Peruvian Biological Diversity and to the Collective Knowledge of the Indigenous Peoples, which last year recorded the second highest number of cases since the Commission's inception, clearly reflecting the urgency of addressing this issue.
103. The solution that Peru and other countries consider most appropriate and that we have proposed here and in other forums is to include the obligation to disclose the origin of the resources and traditional knowledge. Article 29 of the TRIPS Agreement does not suffice, as it does not require patent applicants to disclose the country of origin or provide evidence of compliance with prior informed consent and benefit-sharing. We believe that including the obligation to disclose the source would prevent cross-border misappropriation of our genetic resources and associated traditional knowledge and the issuance of erroneous patents.
104. Lastly, beyond the fact that the topic is discussed in other forums under other approaches, we believe that the WTO has an important role it should take on. To start, allowing the CBD Secretariat to provide further information on the subject and on how both instruments can be mutually reinforcing and supportive as well as updating the Secretariat's documents in order to progress with these discussions.